Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Corneal collagen cross-linking with riboflavin/ultraviolet A (CXL) is a method for the treatment of progressive keratectasia.1 2 In 60% of patients, CXL leads to arrest of progression, and in 40%, even a regression of Kmax values is observed.2 Here, we report three cases that did not display regression but rather displayed a massive remodelling with Kmax reduction of up to 9.5 dioptres (D), accompanied by formation of a deep stromal opacity and a distinct increase in best spectacle-corrected visual acuity (BSCVA).
Three eyes of three patients with progressive keratoconus were included in this interventional case series. Progression was defined as an increase in Kmax>1.0 D within 12 months.3 Pre- and postoperative examinations included corneal topography (Keratograph C, Oculus, Wetzlar, Germany), Scheimpflug imaging (Pentacam, Oculus, Wetzlar, Germany) and slit-lamp examination. CXL was performed as published previously.4
For an overview of corneal characteristics, please refer to table 1.
- In this window
- In a new window
A 27-year-old man (case 1) was referred to us for bilateral keratoconus in April 2007. Previous topographies …
Competing interests None.
Patient consent Obtained.
Ethics approval Ethics approval was provided by the cantonal ethics committee of the Canton of Zurich.
Provenance and peer review Not commissioned; externally peer reviewed.